EMAIL THIS PAGE TO A FRIEND

Neoplasma

Management and results of treatment of breast cancer patients having sentinel lymph node micrometastases.


PMID 24824931

Abstract

According to current therapeutic guidelines, finding micrometastases in the sentinel node (SLN) of a patient with non-advanced breast cancer is not an absolute indication for adjuvant axillary lymph node dissection (ALND). This work presents our experiences regarding this clinical problem. 1071 breast cancer patients were referred for sentinel node biopsy between January 2004 and December 2011. Metastases were found in 245 of the removed lymph nodes. In 49 patients lymph node changes turned out to be micrometastases or isolated tumor cells (ITC). ALND was performed in 38 cases of sentinel node micrometastases or ICTs. In three patients involvement of other axillary lymph nodes was found in the studied tissue material (7.9% vs. 37.9% for metastases >2mm). The remaining patients with micrometastases in the SLN (11/49) were treated conservatively. No local axillary recurrences or neoplastic metastases were found in this group of patients with SLN micrometastases. Mean follow-up period in patients who had undergone ALND was 18.0 months (4 to 60 months) and 21.4 months (9-40 months) in patients without ALND. Non-radical surgical treatment in the presence of SLN micrometastases in patients with non-advanced breast cancer does not lead to therapeutic failure (local axillary recurrences, distant metastases). Obtaining favorable outcomes of conservative treatment in the analyzed group of patients does not require additional modification of the adjuvant therapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1306027 ANTI-CHK(N-TERMINAL) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1405616
Anti-CHKA antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV53583
Anti-CHKA antibody produced in rabbit, affinity isolated antibody
HPA024153
Anti-CHKA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410167
Anti-CHKA antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1401074
Anti-CHKB antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA018797
Anti-CHKB antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1408560
Anti-CHKB antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1407519
Anti-CMPK antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA053730
Anti-CMPK1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA058604
Anti-CMPK1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2107657
Anti-CMPK1 antibody produced in rabbit, affinity isolated antibody
SAB1410948
Anti-CMPK1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1402586
Monoclonal Anti-CMPK antibody produced in mouse, clone 1D7, purified immunoglobulin, buffered aqueous solution